A 4Kscore of 17 means you have a 17% estimated probability of having aggressive prostate cancer found on biopsy. The score falls in the second-highest of four risk intervals the FDA uses to evaluate the test, placing it in the 10 to 20 range where the actual likelihood of finding a high-grade tumor is roughly 1 in 5.
What the 4Kscore Measures
The 4Kscore is a blood test designed to give a more specific picture of prostate cancer risk than a standard PSA test alone. It measures four related proteins produced by prostate tissue: total PSA, free PSA, intact PSA, and a protein called human kallikrein-related peptidase 2. An algorithm combines these four blood markers with your age to generate a single number between 0.1 and 100, representing your percent probability of having high-grade prostate cancer on biopsy.
“High-grade” in this context means a Gleason score of 7 or higher. Gleason scoring describes how abnormal prostate cancer cells look under a microscope. Scores of 6 or below are considered low-grade, slow-growing cancers that often don’t need immediate treatment. A Gleason 7 or above signals more aggressive disease that is more likely to grow, spread, or require intervention. The entire purpose of the 4Kscore is to estimate the probability of this more dangerous type.
Where a Score of 17 Falls
The FDA divides 4Kscore results into four intervals:
- Below 5: lowest risk
- 5 to under 10: low-moderate risk
- 10 to under 20: moderate-high risk
- 20 and above: highest risk
A score of 17 sits in the 10-to-20 bracket. In clinical validation studies reviewed by the FDA, men in this bracket had a 19.7% chance of being diagnosed with high-grade prostate cancer on biopsy. That means roughly 4 out of 5 men in this range did not have aggressive cancer found, but roughly 1 in 5 did. It’s not a diagnosis, but it’s a meaningful signal that warrants a serious conversation with your urologist about next steps.
Why This Test Exists Alongside PSA
The standard PSA blood test is a useful screening tool, but it has a well-known limitation: it flags many men who don’t actually have dangerous cancer. An elevated PSA can result from an enlarged prostate, an infection, recent physical activity, or slow-growing cancer that would never cause harm. This leads to a large number of biopsies that come back negative or find only low-grade disease.
The 4Kscore was developed to sit between an abnormal PSA result and a biopsy decision. In routine clinical practice, it has been shown to reduce biopsy rates by approximately two-thirds. One large implementation study found a 64.6% reduction in the number of patients referred for prostate biopsy after 4Kscore testing was added to the decision-making process. For men with low scores, that means avoiding an invasive procedure they likely didn’t need. For men with higher scores, it provides stronger justification to proceed.
What Typically Happens Next
There is no single, universal cutoff that automatically triggers a biopsy. The National Comprehensive Cancer Network (NCCN) has specifically noted that no optimal threshold has been established for the 4Kscore. Instead, the result is one piece of information your urologist weighs alongside other factors: your PSA level, the results of a digital rectal exam, your family history, your age, and your overall health.
At a score of 17, many urologists will recommend either a prostate biopsy or an MRI of the prostate as a further step. An MRI can identify suspicious areas that may be targeted during biopsy, improving accuracy. Some clinicians use the MRI findings to refine the decision further, particularly for men in this middle-risk zone where the answer isn’t clear-cut in either direction.
If a biopsy is recommended, the procedure typically involves taking small tissue samples from the prostate using an ultrasound or MRI-guided needle. Results usually come back within one to two weeks. If no high-grade cancer is found, your urologist will likely recommend ongoing monitoring with periodic PSA checks and possibly repeat 4Kscore testing. If high-grade cancer is detected, treatment options depend on the specific grade and stage, and range from active surveillance for borderline cases to surgery or radiation for more advanced disease.
Putting the Number in Perspective
A 17% risk can feel alarming, but it helps to frame it clearly: there is an 83% chance that a biopsy would not find aggressive prostate cancer. At the same time, 17% is meaningfully above the lower risk brackets. Men scoring below 5 have roughly a 4% chance of high-grade disease on biopsy. Men scoring 20 or above face much steeper odds. A score of 17 places you in a zone where the risk is real enough that ignoring it would be unwise, but not so high that aggressive cancer is the most likely outcome.
The score also reflects a single point in time. It’s based on the blood protein levels measured on the day your sample was drawn. PSA and its related markers can fluctuate for many reasons, which is why your urologist considers the full clinical picture rather than treating any single number as a definitive answer.